Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Prime Medicine, Bristol Myers Squibb
Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
Prime Medicine (NASDAQ:PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb (NYSE:BMY), which includes a $55M equity investment. Under the deal, Prime (PRME) will receive $55M upfront and the $55M investment.
Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb
Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is rarely straightforward.
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
Bristol, Prime Medicine in deal to develop T-cell therapies
Prime Medicine and Bristol Myers Squibb are collaborating on next-generation ex vivo T-cell therapies. Read more here.
Prime Medicine Inks Strategic Research Collaboration And License Agreement With Bristol Myers Squibb
Prime Medicine, Inc. (PRME) announced Monday a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY)
Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb
Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, including up to $1.4 billion in development milestones and more than $2.1 billion in commercialization milestones, along with royalties on net sales.
Prime Medicine soars as it inks research collab with BMS
Cambridge, USA-based Prime Medicine saw its shares rocket more than 38% to $4.78 today, as it revealed a strategic research collaboration and license agreement with Bristol Myers Squibb.
Prime Medicine Inks Up-to-$3.5B Collaboration with BMS, Narrows Pipeline
Prime Medicine will partner with Bristol Myers Squibb (BMS) to develop and commercialize an unspecified number of reagents for ex vivo T-cell therapies through a collaboration that could generate more than $3.
Prime to narrow gene editing research as it strikes deal with Bristol Myers
The high-profile biotech is zeroing in on programs that serve as proof points for its technology, while seeking partners for other assets.
FierceBiotech
10h
BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline
Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...
BioSpace
2h
Gene Editor Prime Medicines Signs BMS Cell Therapy Deal, Reprioritizes Pipeline
In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...
6h
on MSN
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Monday. Shares of Prime Medicine, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
NBA Hall of Famer dies
‘Ring of fire’ eclipse in Oct
Helene wreaks havoc
Red Sox honor radio voice
Israel announces operation
Blocks songs from artists
Grammy-winning singer dies
Illegal cloning sentencing
NYC tunnel shutdown
To receive FEMA briefing
Signals more rate cuts
Mich. nuclear plant to restart
Harris' Las Vegas rally
Nepal floods: Death toll rises
Ozzie Virgil Sr. dies at 92
US wins Presidents Cup
37 militants killed in Syria
Newsom vetoes AI safety bill
To sue Google, Samsung
Oil prices climb
Sells stake in DirecTV
US port strike looms
Line Fire prompts evacuation
Defensive Player of the Year
Three PFLP leaders killed
Seeks bribery dismissal
Crew-9 astronauts at ISS
Feedback